Robigo
Robigo engineers biological crop-protection solutions that use targeted microbes to control plant pathogens while preserving beneficial organisms.
UndisclosedSeries A
ParticipantIV
Illumina Ventures
illuminaventures.com ↗Activity from announced rounds
Activity in this selectionUnited States · Oct 16, 2026 · Jul 19, 2026
Illumina Ventures invests in genomics and precision health, supporting companies that turn biological research into products and services.
Investment focus
The firm describes its role as building an ecosystem around advances in human health. Its published portfolio spans therapeutic development, enabling research technologies and biological applications.
Activity recorded by RoundOS
RoundOS examples include Encoded Therapeutics’ gene-regulation medicines, SonoThera’s gene-delivery platform and Syntax Bio’s cell-therapy technology. Robigo adds biological crop protection to the recorded activity. These are selected financings in the database, not an exhaustive portfolio.
Sources
- Rounds participated in
- 2
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $275M 1 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionEncoded Therapeutics Inc.
Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome.
$275MSeries F
Participant